Literature DB >> 7638742

Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete?

R A Decker1, M L Peacock, M J Borst, J D Sweet, N W Thompson.   

Abstract

BACKGROUND: Recent identification of RET mutations in multiple endocrine neoplasia type 2A (MEN 2A) allows a DNA-based approach to diagnosis in lieu of calcitonin sampling. To prospectively evaluate the efficacy of mutational analysis, genetic screening was performed in 124 patients (53 male, 71 female; age, 1 month to 80 years) at risk for MEN 2A referred over 3 months.
METHODS: Analysis used genomic DNA and a polymerase chain reaction-based denaturing gradient gel electrophoresis strategy for mutation detection at RET codons 609, 611, 618, 620, and 634. Ninety-three of 124 patients were from established MEN 2A kindreds (group A), and screening replaced calcitonin testing. Twenty-one of 124 patients (group B) represented index cases of medullary thyroid carcinoma (MTC), and DNA analysis was performed to distinguish sporadic from hereditary disease. Ten patients (group C) had modest calcitonin elevations or had undergone thyroidectomy without confirming pathologic results, and testing was undertaken to clarify status.
RESULTS: Group A: RET mutations occurred in 29 (median age, 10 years) of 93 patients, 14 of whom underwent thyroidectomy. No false-positive results were observed. Group B: five (24%) of 21 patients with seemingly sporadic MTC had RET mutations at codons 618 (one), 620 (one), or 634 (three). Group C: Nine of 10 patients with alleged MEN 2A had genetically negative results.
CONCLUSIONS: Denaturing gradient gel electrophoresis reliably detects MEN 2A. Modest calcitonin elevations may lead to a false-positive diagnosis of MTC. DNA testing is the optimal approach to evaluating MEN 2A. Index cases of sporadic MTC should also undergo DNA analysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7638742     DOI: 10.1016/s0039-6060(05)80332-0

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Clinical experience over 48 years with pheochromocytoma.

Authors:  R E Goldstein; J A O'Neill; G W Holcomb; W M Morgan; W W Neblett; J A Oates; N Brown; J Nadeau; B Smith; D L Page; N N Abumrad; H W Scott
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

Review 2.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

3.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

Review 4.  RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.

Authors:  F Pacini; R Elisei; C Romei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

5.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

Review 6.  Multiple endocrine neoplasias type 2B and RET proto-oncogene.

Authors:  Giuseppe Martucciello; Margherita Lerone; Lara Bricco; Gian Paolo Tonini; Laura Lombardi; Carmine G Del Rossi; Sergio Bernasconi
Journal:  Ital J Pediatr       Date:  2012-03-19       Impact factor: 2.638

Review 7.  Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Marcelo Augusto Santos; Marcos R Tavares; Rodrigo A Toledo; Joya Emilie de Menezes Correia-Deur
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

8.  Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas.

Authors:  S Uchino; S Noguchi; M Adachi; M Sato; H Yamashita; S Watanabe; T Murakami; M Toda; N Murakami; H Yamashita
Journal:  Jpn J Cancer Res       Date:  1998-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.